The National Health Surveillance Agency (Anvisa) approved, on Wednesday (13), the Varanigo, the first daily tablet indicated to treat specific types of brain cancer, including low-grade diffuse gliomas with mutations in HDI 1 or 2 enzymes.
Developed by the pharmacist Servier, the drug acts by blocking enzymes that stimulate the growth of tumor cells. It is recommended for patients from 12 years old who have had surgery and do not need radiotherapy or immediate chemotherapy.
According to Agência Brasil, approval represents the greatest advance in glioma treatment in the last 20 years. This type of brain tumor is the most common and, in its low degree form, mainly affects children, adolescents and young adults.
Varanigo should be taken once a day, offering an innovative and less aggressive therapeutic alternative to patients who do not yet need more invasive treatments.
